# Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH)

> **NCT02039219** · PHASE2 · TERMINATED · sponsor: **Naga P. Chalasani** · enrollment: 19 (actual)

## Conditions studied

- Alcoholic Hepatitis

## Interventions

- **DRUG:** Placebo
- **DRUG:** 10 mg Obeticholic Acid (OCA)

## Key facts

- **NCT ID:** NCT02039219
- **Lead sponsor:** Naga P. Chalasani
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-11-03
- **Primary completion:** 2017-07-30
- **Final completion:** 2018-01-29
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Post-marketing reports of hepatotoxicity associated with obeticholic acid emerged in June 2017, investigators temporarily halted patient recruitment June 2017.
- **Last updated:** 2020-01-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02039219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02039219, "Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH)". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT02039219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*